Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 281 - 300 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
When it Rains, it Pours, Another Patent Win; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Two More Vascepa Patents Allowed, Including Key ''889; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Announces Allowance of ''145 Patent Application from MARINE Family; Additional NOAs Expected Soon; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
145 Patent Allowed; Reiterate Buy and $26 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 2, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2Q12 Results; The 3 Path Puzzle for Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Less Aggressive Tone on Self-Launch Should Calm Nerves; Timing of NCE Decision not a Lock; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Approved, See Upside Ahead of Launch; Target to $26
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Approved; NCE/IP and Strategic Decision Remain in Focus
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.